title: The effect of vildagliptin therapy on atherogenic postprandial remnant particles and LDL particle size in subjects with type 2 diabetes.
authors.forename: N
authors.initials: N
authors.lastname: Matikainen
authors.forename: M-R
authors.initials: MR
authors.lastname: Taskinen
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood / Q000737:chemistry; D053298:Chylomicron Remnants / Q000097:blood* / Q000737:chemistry; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D059305:Diet, High-Fat / Q000009:adverse effects; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D006801:Humans; D006943:Hyperglycemia / Q000517:prevention & control; D006949:Hyperlipidemias / Q000517:prevention & control*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008077:Lipoproteins, LDL / Q000097:blood* / Q000737:chemistry; D062407:Meals; D009570:Nitriles / Q000627:therapeutic use*; D010316:Particle Size; D019518:Postprandial Period; D011759:Pyrrolidines / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood; D000077597:Vildagliptin
chemical_list: D015415:Biomarkers; D053298:Chylomicron Remnants; D054873:Dipeptidyl-Peptidase IV Inhibitors; D000960:Hypolipidemic Agents; D008077:Lipoproteins, LDL; D009570:Nitriles; D011759:Pyrrolidines; D014280:Triglycerides; D000077597:Vildagliptin; D000218:Adamantane